Enter inventor name

Rita M Steeves

USPTO Granted Patents = 13 (Patent Applications = 5)

EPO Patents = 1

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 289(Granted Patents)

Location History:

Stonehame, MA (US) (2012)
Stoneham, MA (US) (2011 - 2024)

Company Filing History:

Acceleron Pharma Inc.

patents

2 out of 1,373

The Brigham and Women's Hospital, Inc.

Janssen Biotech, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11951156 - Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor (2024-04-09),

2. 11008377 - Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptides (2021-05-18),

3. 10981973 - Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide (2021-04-20),

4. 10682392 - Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein (2020-06-16),

5. 10316076 - Transforming growth factor-beta receptor type II fusion polypeptides (2019-06-11),

6. 9809637 - Transforming growth factor beta receptor II fusion polypeptides (2017-11-07),

7. 8603483 - Anti-integrin immunoconjugates, methods and uses (2013-12-10),

8. 8388960 - Elimination of heterogeneous or mixed cell population in tumors (2013-03-05),

9. 8198417 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates (2012-06-12),

10. 8163888 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates (2012-04-24),

11. 8137669 - Elimination of heterogeneous or mixed cell population in tumors (2012-03-20),

12. 8088387 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates (2012-01-03),

13. 7989598 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates (2011-08-02),

Title: Rita M Steeves: Innovator in Pulmonary Hypertension Treatments

Introduction

Rita M Steeves is a prominent inventor based in StoneHame, Massachusetts, recognized for her significant contributions to the pharmaceutical field with a total of 13 patents. Her groundbreaking work focuses particularly on innovative methodologies for treating pulmonary hypertension and related disorders, showcasing her dedication to advancing medical technology.

Latest Patents

Among her latest patents is a method for treating pulmonary hypertension using a ligand-binding domain of a TGF-beta type II receptor. This invention outlines pharmaceutical compositions that incorporate a TGF-β ligand trap and presents various methods for utilizing this trap to treat, prevent, or slow the progression of pulmonary hypertension (PH). Furthermore, the invention addresses a spectrum of other health issues, including conditions associated with excessive TGF-β signaling, pulmonary vascular remodeling, and diseases that involve GDF15 signaling. Another notable patent focuses on treating fibrotic disorders through the administration of transforming growth factor beta receptor II fusion polypeptides. This particular work highlights the creation of polypeptides designed to selectively antagonize the TGF-βRII ligand, offering new therapeutic avenues for TGF-β associated disorders.

Career Highlights

Rita Steeves has been associated with several esteemed organizations during her career. Notable companies in her professional history include Immunogen, Inc. and Acceleron Pharma Inc., where she applied her innovative mind to develop treatments for critical health conditions. Her work has noticeably impacted the pharmaceutical landscape, particularly in addressing complex ailments.

Collaborations

Throughout her career, Rita has collaborated with several fellow innovators, including colleagues Ravi V J Chari and Ravindra Kumar. These partnerships have fostered a rich exchange of ideas and have contributed to the advancement of her research initiatives.

Conclusion

Rita M Steeves exemplifies the spirit of innovation, pushing the boundaries of medical treatments for pulmonary hypertension and fibrosis. With her impressive portfolio of patents and collaborative efforts, she continues to pave the way for future advancements in health solutions, solidifying her status as a leading inventor in her field.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com